Dublin, Ireland – January 19, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Thomas Dittrich will assume his role as Chief Financial Officer, and become an Executive member of the Board of Directors and a member of the Executive Committee, on March 19, 2018.
This announcement is made in compliance with LR 9.6.12.
For further information please contact:
|Christoph Brackmann||[email protected]||+41 795 432 359|
|Sun Kim||[email protected]||+1 617 588 8175|
|Robert Coates||[email protected]||+44 203 549 0874|
|Lisa Adler||[email protected]||+1 617 588 8607|
|Katie Joyce||[email protected]||+1 781 482 2779|
NOTES TO EDITORS
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.